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SUMMARY
Aims: Although compelling evidence suggests that human hypothalamic hamartoma (HH)
is intrinsically epileptogenic for gelastic seizures, the molecular mechanisms responsible for
epileptogenesis within HH remain to be elucidated. The aim of this study was to test the
hypothesis that hyperactivation of BDNF-TrkB signaling pathways in surgically resected HH
tissue is a possible mechanism for downregulation of KCC2 expression, which in turn
underlies GABA-mediated excitation within HH. Methods: Activation of three major
BDNF-TrkB signaling pathways including MAPKs, Akt, and PLCc1 were evaluated in surgi-
cally resected HH tissue (n = 14) versus human hypothalamic control tissue (n = 8) using
combined methodologies of biochemistry, molecular biology, cell biology, and electrophysi-
ology. Results: Our data show that compared with hypothalamic control tissue, in HH
tissue, (i) activation of TrkB and expression of mature BDNF are elevated; (ii) MAPKs
(including ERK1/2, p38, and JNK), Akt, and PLCc1 are highly activated; (iii) KCC2 expres-
sion is downregulated; and (iv) pharmacological manipulation of TrkB signaling alters HH
neuronal firing rate. Conclusion: Our findings suggest that multiple BDNF-TrkB signaling
pathways are activated in HH. They act independently or collaboratively to downregulate
KCC2 expression, which is the key component for GABA-mediated excitation associated
with gelastic seizures.
Introduction
Human hypothalamic hamartoma (HH) is a developmental mal-
formation that occurs in the region of the tuber cinereum and
inferior hypothalamus. HH is associated with diverse neurological
and endocrine disorders, including epilepsy, cognitive impair-
ment, behavioral disturbances, and central precocious puberty
[1,2]. The epileptic syndrome in HH patients is often characterized
by gelastic (laughing) seizures beginning in early infancy, fol-
lowed by the development of additional seizure types, which are
usually refractory to available anti-epilepsy drugs (AEDs) and
alternative therapies [2]. HH is a human model of subcortical
epilepsy [3]. There is now compelling evidence that HH is intrinsi-
cally epileptogenic for gelastic seizures, including seizure record-
ings with surgically implanted electrodes and positive results for
seizure control with surgical resection [4,5]. However, the molec-
ular and cellular mechanisms responsible for epileptogenesis
within HH are largely unknown.
Electrophysiological features of HH neurons suggest that
gamma-aminobutyric acid (GABA)-mediated excitation plays an
important role in epileptogenesis [6–8]. Binding of GABA to its
ionotropic GABAA receptor, a ligand-gated Cl
 channel, usually
leads to the hyperpolarization of neuronal membranes via the
influx of Cl ions [9]. However, GABA can exert an excitatory
role in immature brain and in mature brain under certain patho-
physiological conditions including epilepsy [10]. The key mecha-
nism underlying GABA-induced neuronal excitation relates to the
intracellular Cl concentration and the transmembrane Cl gradi-
ent. Maintenance of the Cl gradient required for hyperpolarizing
ionotropic responses (relatively low intracellular Cl concentra-
tion) is attributable to the functional expression of the mature
neuron-specific K+-Cl cotransporter, KCC2 [11]. We have
observed that most large HH neurons, which appear to be excit-
atory projection-type pyramidal neurons, demonstrate depolariza-
tion and increased firing in response to GABA, in association with
relatively low levels of KCC2 expression and elevated intracellular
Cl concentrations [6,7,12,13]. As a result, GABA exerts an excit-
atory role in these neurons, potentially contributing to seizure
genesis. Here, we hypothesized that downregulation of KCC2
expression related to alterations in key intracellular signal
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transduction pathways in HH tissue that have not been previously
investigated.
Brain-derived neurotrophic factor (BDNF), a member of the
family of neurotrophins, is essential for neuronal development
and is implicated in the modulation of synaptic function and plas-
ticity [14,15]. BDNF exerts its biological effects via its high-affinity
receptor, TrkB, a member of the tropomysin-related kinase (Trk)
family of the receptor tyrosine kinase (RTK) superfamily. BDNF
binding leads to TrkB dimerization and intrinsic kinase activation.
This results in trans-autophosphorylation on multiple tyrosine
residues within the intracellular domain of TrkB, which potenti-
ates the receptor tyrosine kinase activity and creates docking sites
for adaptor proteins, such as Shc and phospholipase Cc (PLCc).
These adaptor proteins couple the receptor to several important
intracellular signaling cascades, including the Ras-mitogen-acti-
vated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K)-
Akt, and PLCc-Ca2+ pathways [16,17]. These pathways regulate
gene expression and protein translation [18].
It has been previously reported that TrkB activation can reduce
GABAA receptor-mediated responses of CA1 pyramidal cells
[19,20]. One possible mechanism by which TrkB impairs GABAer-
gic inhibition is through downregulation of KCC2 expression. This
is supported by the following findings: (i) BDNF-mediated TrkB
activation resulted in reduced KCC2 expression and impaired
neuronal Cl extrusion in rat hippocampal slice cultures; (ii) in
kindled mice, KCC2 expression was downregulated in hippocam-
pus with a spatio-temporal profile complementary to the upregu-
lation of BDNF and TrkB; (iii) hippocampal slices derived from
transgenic trkB mutant mice (trkBSHC/SHC and trkBPLC/PLC) sug-
gested that activation of both Shc and PLCc signaling cascades is
required for TrkB-mediated downregulation of KCC2 [11,21,22].
In this study, we aimed to test the hypothesis that hyperactiva-
tion of BDNF-TrkB signaling pathways in surgically resected HH
tissue is a possible mechanism for downregulation of KCC2
expression, which in turn underlies GABA-mediated excitation
within HH.
Materials and Methods
Clinical Profiles of Study Subjects
The use of surgically resected tissue in this study was approved by
the Institutional Research Board (IRB) of St. Joseph’s Hospital and
Medical Center. HH tissue was extracted from 14 patients (mean
age 8.5 years, range 0.7 to 40.8 years; 7 [50%] were female). All
patients had treatment-resistant epilepsy and had failed at least
three AEDs. The mean age for seizure onset was 5.6 months
(range 1 to 18 months; 7 [50%] had first seizure activity before
one month of age). At the time of surgery, 6 (43%) had only
gelastic seizures, while 8 (57%) had multiple seizure types. All
patients had gelastic seizures at some point during their clinical
course. Twelve patients (86%) experienced at least one seizure
every day, while two patients (14%) had at least one seizure every
month. At surgery, nine patients (64%) were taking at least 2
AEDs (range 0 to 4 AEDs). Prior treatment for epilepsy had
included gamma knife radiosurgery in three patients (21%).
Seven patients (50%) had a history of intellectual disability (intel-
ligence quotient [IQ] or developmental quotient [DQ] <50). Four
patients (29%) had a history of central precocious puberty. None
of the patients in this cohort had Pallister-Hall syndrome or other
identified syndromes. The mean HH lesion volume was 3.2 cm3
(range 0.2 to 20 cm3). All HH tissue used in Western blot analysis
was snap frozen on dry ice immediately after surgical resection
and stored at 80°C until assay.
Human Control Tissue
Postmortem (frozen) hypothalamic tissue derived from 8 normal
human donors (two females and six males) was obtained from
the Harvard Brain Tissue Resource Center, the Human Brain &
Spinal Fluid Resource Center (West Los Angles Healthcare
Center), and the University of Maryland. Brain tissue was col-
lected within 4 h after death. The mean age was 39 years, range
12.7–78 years.
Antibodies and Reagents
Primary antibodies used are detailed in Table S1. The Trk kinase
inhibitor K252a was from EMDMillipore.
RNA Extraction and Real-Time RT-PCR
Total RNAs were extracted from tissue using QIAzol Lysis Reagent
(QIAGEN, Valencia, CA, USA). cDNA synthesis and quantitative
PCR were performed as previously described [6,7,23].
Protein Extraction, SDS-PAGE, and
Immunoblotting
Tissue samples (~50 mg) were dissected from frozen sections,
weighed, thawed on ice, and lysed in ice-cold RIPA buffer
(25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium
deoxycholate, and 0.1% SDS) containing protease and phospha-
tase inhibitors [24]. Following homogenization with plastic pestles
that tightly fit microtubes, the homogenates were sheared 5 times
by passing through single-use needles (0.4 9 13 mm) (Becton
Dickinson, Franklin Lakes, NJ, USA) and solubilized for 1 h on
ice. After centrifugation, the supernatants (protein extracts) were
collected, quantitated and resolved on SDS-PAGE [23,24]. Immu-
noblotting with antibodies (Table S1) was performed using stan-
dard procedures. Immunoblotting signals were detected with
SuperSignal chemiluminescent substrate (Pierce) and images were
captured using a Kodak 4000 MMmolecular imager [23,25,26].
Immunohistochemical Staining
Tissue sections were prepared and immunostaining with a goat
anti-KCC2 antibody (R-14) (Santa Cruz Biotechnology) was per-
formed as described previously [6,8].
Patch-Clamp Recordings in HH Slices
Acute HH slices were prepared as previously described [6–8]. The
conventional whole-cell recordings were made using a patch-
clamp amplifier (Multiclamp 700A, Axon Instruments, Molecular
Devices, Sunnyvale, CA, USA) under infrared-DIC (differential
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interference contrast) microscopy. The patch-pipette solution con-
tained (in mM): 140 K+-gluconate, 5 KCl, 10 HEPES, 0.2 EGTA, 2
MgCl2, 4 MgATP, 0.3 Na2GTP and 10 Na2-phosphocreatine (pH7.3
with KOH). HH neuron action potential was recorded in current-
clamp mode. Whole-cell access resistance <20 MΩ was accepted
for experiments. The series resistance was not compensated in this
study. Typically, data were acquired at 10 kHz, filtered at 2 kHz,
displayed and digitized online (Digidata 1322 series A/D board,
Axon Instruments), and stored to a hard drive. Data acquisition
and analyses of action potential firing using patch-clamp whole-
cell recording in current-clamp mode were done using Clampex
9.2 and Clampfit 9.2 (Axon Instruments), respectively, and results
were plotted using Origin 5.0 (Microcal, OriginLab, Northampton,
MA, USA). The standard external solution contained (in mM):
150 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, 10 glucose and 10 HEPES (pH
adjusted to 7.4 with Tris-base). All experiments were performed at
room temperature (22  1°C).
Densitometry and Statistical Analysis
Densitometric quantification of digital immunoblotting images
was performed using Kodak Molecular Imaging Software (Version
4.0). Data were given as mean  SEM. The significance (P value)
was calculated with analysis of variance (ANOVA) or paired or
unpaired t-tests when applicable. Pearson correlation analysis was
performed using GraphPad Prism (Version 5.0) to evaluate the
relationships among the variables of interest. P < 0.05 was consid-
ered statistically significant.
Results
Enhanced Overall Tyrosine Phosphorylation
Signals in HH Tissue
Tyrosine phosphorylation is one of the key steps in intracellular
signal transduction and regulation of enzymatic activity in
eukaryotic cells, and perturbations in tyrosine phosphorylation
underlie many human diseases [27,28]. We sought to assess the
overall tyrosine phosphorylation levels in both HH tissue and nor-
mal human hypothalamus (control) by immunoblotting analysis.
Proteins extracted from HH (n = 14) and control (n = 8) tissue
were resolved on SDS-PAGE and further analyzed by immuno-
blotting with a mouse monoclonal anti-phosphotyrosine antibody
(pTyr, 4G10). This antibody is very sensitive and reliable for detec-
tion of tyrosine phosphorylation and has been successfully used in
our previous studies [24–26]. Our results indicated that the overall
phosphorylation level in HH tissue was markedly higher than in
control tissue (Fig. S1).
This experimental approach utilizes quantitative assessment of
phosphorylated protein levels relative to total protein levels by
densitometric analysis of immunoblotting results. This technique
has been successfully employed in our previous studies [23–26].
However, the impact of postmortem interval (PMI) on protein
phosphorylation and total protein levels could be a concern given
the nature of tissue collection. To address this, we performed a set
of immunoblotting experiments using rat brain tissues collected
1–4 h after death of the animals at room temperature (22  1°C).
Representative images of immunoblotting with anti-active-ERK1/
2 (pERK1/2) and anti-total ERK1/2 blots are shown in Fig. S2.
Both antibodies have been well documented in our previous stud-
ies [23,24,26]. Our results consistently demonstrated that PMI
had very little effect on both protein phosphorylation and total
protein levels at least within the initial 4 h after death (Fig. S2).
This ensures the accuracy of our immunoblotting data throughout
the study.
Elevated Phosphorylation of TrkB and
Expression of BDNF in HH Tissue
Increased overall phosphorylation in HH versus control tissue
prompted us to further examine BDNF-TrkB signaling. We first
assessed TrkB phosphorylation by immunoblotting with an anti-
phospho-TrkB (Tyr816) (pTrkB) antibody, and detected enhanced
immunoreactive signals in HH versus control group (Figure 1A).
(A)
(B) (C) (D)
Figure 1 Enhanced BDNF-TrkB signaling in HH. (A–D) Elevated phosphorylation of TrkB in HH. Total proteins were extracted from HH and normal human
hypothalamic control tissue specimens and equal amounts of proteins were subjected to SDS-PAGE and analyzed by immunoblotting with anti-phospho-
TrkB (Tyr816) (pTrkB) and anti-TrkB, respectively (A). Densitometric analysis results of immunoblotting data of anti-pTrkB (B) and anti-TrkB (C), respectively,
from 14 HH and 8 controls are shown. (D) Elevated BNDF expression (mRNA) in HH. Total RNAs were extracted from HH (n = 16) and control (n = 3) tissue
specimens and used for real-time RT-PCR analysis to measure the mRNA level of mature BDNF relative to that of human GAPDH. *P < 0.05; **P < 0.01.
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In contrast, the expression of TrkB was detected by anti-TrkB
antibody in all samples (Figure 1A). The levels of pTrkB and total
TrkB were further estimated by densitomeric analyses (Figure 1B,
C). Our results showed that TrkB phosphorylation was signifi-
cantly enhanced in HH compared with the control (P < 0.05)
(Figure 1B).
The elevated phosphorylation of TrkB could be due to excessive
expression of BDNF (the specific ligand for TrkB) in HH tissue. To
test this, we compared the mRNA levels of mature BDNF between
HH and control groups by real-time RT-PCR. As in Figure 1D,
when normalized to the mRNA level of a housekeeping gene
(GAPDH), the expression level of BDNF in HH was significantly
higher than that in the control group (P < 0.01).
Hyperactivation of MAPKs in HH Tissue
We next sought to assess the TrkB downstream signaling cascades.
MAPKs are a family of serine/threonine kinases that play impor-
tant roles in signal transduction initiated by RTKs including Trks
[29]. MAPKs mainly include ERK1/2 (p44/p42 MAPKs), c-Jun N-
terminal kinases (JNKs), and p38 MAPK [29]. Thus, we examined
the activation status of these three major MAPKs. Immunoblot-
ting with anti-active p38 (p-p38), anti-active JNK1 (pJNK1), and
anti-active ERK1/2 (pERK1/2), respectively, revealed that each
antibody detected corresponding active forms of MAPKs present
in HH tissue (Figure 2A). In contrast, the signals were almost neg-
ligible in all controls. Immunoblotting with anti-ERK antibody
confirmed the equal protein loading (Figure 2A). Densitometric
analyses further revealed that the respective pJNK1, p-p38, and
pERK (but not ERK) levels were significantly higher in HH versus
control tissue (p-p38, P < 0.05; pJNK1, P < 0.01; pERK1/2,
P < 0.05) (Figure 2B–E). These findings suggest that all three
major MAPK pathways were highly activated in HH tissue.
Interrelationship Between Active Akt and PTEN
in HH Tissue
In parallel with the MAPK pathways, Akt is another key signaling
molecule downstream of RTKs [30]. Akt is a serine/threonine
kinase and its activity can be impacted by the tumor suppressor
PTEN (phosphatase and tensin homolog deleted on chromosome
10), which is upstream of Akt. PTEN is considered as the primary
negative regulator of Akt [31]. Loss of PTEN or PTEN mutation is
the most common cause of hyperactivation of Akt signaling in
many human diseases [32]. Here, we assessed the Akt activation,
PTEN expression, and their interrelationship by immunoblotting
with anti-phospho-Akt (pAkt), anti-Akt, and anti-PTEN, respec-
tively, combined with densitometric analyses (Figure 3). Our
results showed that the pAkt (but not Akt) level was significantly
higher in HH than that in the control group (P < 0.05) (Fig-
ure 3A–C). Surprisingly, the PTEN level in HH was also higher
than that in the control (P < 0.05) (Figure 3A,D).
It is known that PTEN possesses a C-terminal, noncatalytic reg-
ulatory domain with three phosphorylation sites (Ser380, Thr382,
and Thr383) that regulate PTEN stability and may affect its biolog-
ical activity [33]. To confirm our findings of PTEN expression
herein, we performed immunoblotting with an anti-phospho-
PTEN (Ser380/Thr382/Thr383) (pPTEN) antibody (Figure 3A)
and subsequent quantification (Figure 3E). The results indicated
that the pPTEN level was indeed higher in HH tissue compared
with the control (Figure 3E). Further, pPTEN positively correlated
with PTEN (P < 0.001) (Figure 3F). Collectively, our data sug-
gested that for the comparison between the two groups (HH ver-
sus control), the pAkt level did not exhibit a negative relationship
with the PTEN level as expected. Rather, both were higher in the
HH group than those in the control group. However, when com-
paring the pAkt and PTEN levels within the HH group (n = 14),
we uncovered that pAkt displayed a negative relationship to
PTEN. It seemed that the HH group could be classified into two
subgroups, Low pAkt-High PTEN and High Akt-Low PTEN (Fig-
ure 3G). Correlation analysis further confirmed such an inverse
interrelationship (P < 0.001) (Figure 3H).
Increased PLCc1 Phosphorylation and CaMKII
Expression in HH Tissue
The PLCc/CaMKII (Ca2+/calmodulin-dependent kinase II)
pathway is one of the major pathways that are activated upon
BDNF binding to TrkB [16,17]. Functional expression of CaMKII
(A)
(B) (C)
(D) (E)
Figure 2 Hyperactivation of MAPKs in HH. Proteins extracted from HH
and control tissue specimens were analyzed by immunoblotting with anti-
active JNK (pJNK), anti-active p38 MAPK (p-p38), anti-active ERK (pERK),
and anti-total ERK, respectively (A). Densitometric analysis results of
immunoblotting data of anti-pJNK (B), anti-p-p38 (C), anti-pERK (D), and
anti-ERK (E), respectively, from 14 HH and eight controls are shown.
*P < 0.05; **P < 0.01.
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is regulated by Ca2+/calmodulin complex downstream of PLCc
[16]. The increased TrkB phosphorylation at Tyr816 (the docking
site for PLCc) in HH versus control tissue (Figure 1) prompted us
to further assess this pathway by immunoblotting followed by
desitometric analyses. The results indicated that PLCc1 phosphor-
ylation was significantly enhanced in HH versus control tissue
(P < 0.001) (Figure 4A,B). Our results also revealed that the anti-
CaMKII (pan) antibody detected two isoforms of CaMKII, includ-
ing CaMKII-a (~50Kd) and CaMKII-b (~60Kd), and both were
significantly upregulated in HH versus control tissue (P < 0.01)
(Figure 4C,D). As expected, correlation analysis confirmed the
positive correlation between PLCc1 phosphorylation and CaMKII
expression (P < 0.01) (Figure 4E).
Downregulation of KCC2 in HH Tissue
It has been previously reported that the expression of the K+-Cl
cotransporter KCC2 in adult rat neurons is downregulated follow-
ing epileptiform activity and/or neuronal damage by activation of
BDNF-TrkB signaling [21,22]. Here, we asked whether KCC2
expression was altered in HH in comparison with control tissue.
The immunoblotting and densitometric analysis results indicated
that the KCC2 level in HH tissue was significantly lower than that
in the control (P < 0.01) (Figure 5A,B). Likewise, immunostain-
ing in tissue section slices demonstrated strong anti-KCC2 immu-
noreactivity in controls versus weak signals in HH tissue
(Figure 5C, arrows).
(A)
(B) (C)
(D)
(F)
(E)
(H)
(G)
Figure 3 Profiles of Akt activation and PTEN expression in HH. (A) Proteins extracted from HH and control tissue specimens were analyzed by
immunoblotting with anti-phospho-Akt (pAkt), anti-total Akt, anti-total PTEN, and anti-phospho-PTEN (pPTEN), respectively. (B–E) Densitometric analysis
results of immunoblotting data of anti-pAkt (B), anti-Akt (C), anti-PTEN (D), and anti-pPTEN (E), respectively, from 14 HH and eight controls are shown.
*P < 0.05; **P < 0.01. (F) Correlation analysis indicates a positive relationship between pPTEN and total PTEN levels. (G) Within HH group, pAkt levels
show a negative relationship with PTEN levels. In this display, the HH subject No. 1 was used as a standard for the purpose of densitometric analyses with
its mass set as 50. The HH subjects No. 2–10 had relatively lower pAkt but higher PTEN. Conversely, the HH subjects No. 11–14 had relatively higher pAkt
but lower PTEN. (H) Correlation analysis confirms the negative relationship between pAkt and PTEN within HH group.
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Pharmacological Manipulation of TrkB Signaling
Alters HH Neuronal Firing Rate
As above, we have demonstrated that the BDNF-TrkB signaling is
upregulated, and concomitantly, KCC2 expression is downregu-
lated in HH compared with the control tissue. These findings sug-
gest that activation of BDNF-TrkB signaling may underlie the
KCC2 downregulation and thereby GABA-mediated excitation in
HH. If this is true, HH neuronal firing would be altered if the
BDNF-TrkB signaling is activated or blocked.
We tested this possibility using patch-clamp recordings in
freshly prepared HH slices. As shown in Figure 6A, patch-clamp
current-clamp recording showed that a large-sized HH neuron
exhibited spontaneous, irregular action potential (AP) firing at a
low firing rate (<3 Hz). Bath application of BDNF (10 ng/mL)
increased the HH neuronal firing (Figure 6B). In five large HH
cells tested (from five HH patients), 2 min exposure to BDNF
increased AP firing rate from 2.02  0.75 Hz to 5.06  0.89 Hz
(P < 0.01, paired t-test). Then, we tested the effect of blockade of
BDNF-TrkB signaling on HH AP firing. K252a is a selective inhibi-
tor of Trk kinase activity [34], and has been widely used to verify
BDNF/TrkB-mediated effects [15,35]. Our results showed that
bath application of K252a (10 lM) reduced the AP firing rate in a
large (Figure 6C), but not in a small HH neuron (Figure 6D). Sta-
tistical analysis showed that exposure to K252a for 2 min reduced
the AP firing from 3.34  0.49 Hz to 1.98  0.33 Hz (P < 0.01,
paired t-test, n = 5 from five patients). Together, these results
suggest that the BDNF-TrkB signaling plays an important role in
modulation of HH neuronal function.
Discussion
The goal of our research is to develop a cellular and molecular
model for seizure genesis within HH. Earlier work on surgically
resected HH tissue focused on characterizing the phenotype,
including electrophysiological properties, of the neurons within
HH tissue [6–8,12,36]. We uncovered that most large HH neurons
have the functionally immature property of depolarizing and
firing in response to GABA agonists as a result of elevated intracel-
lular Cl concentration [6,12,13]. These neurons also show
decreased KCC2 expression (relative to small HH neurons) at both
mRNA and protein levels [6,12]. These data suggest that downreg-
ulated KCC2 expression may be causative for depolarizing and
excitatory GABA responses in HH. In the present study, we
explore intracellular signal transduction pathways potentially
related to KCC2 downregulation in HH tissue. Our data show that
compared with normal human hypothalamic control tissue, in HH
tissue, (i) activation of TrkB and expression of mature BDNF are
elevated; (ii) three major BDNF-TrkB signaling pathways, includ-
ing MAPKs, Akt, and PLCc1, are highly activated; and (iii) KCC2
expression is downregulated.
There is no animal model for HH, and consequently research on
the cellular mechanisms resulting in epileptogenesis of HH relies
upon the use of surgically resected human tissue. Obtaining con-
trol material is problematic, as there is a very high surgical pre-
mium on avoiding resection of adjacent tissue when resecting
lesions within the hypothalamus. We make use of human autopsy
control material as the best alternative under these circumstances.
Our data suggest that protein expression and phosphorylation lev-
els are stable during the postmortem time interval necessarily
encountered for control tissue of this nature.
To our knowledge, this is the first report of comprehensive pro-
files of the BDNF-TrkB signaling system in HH, from the expres-
sion level of the ligand (BDNF) to phosphorylation/activation
status of the receptor (TrkB) and its downstream signaling cas-
cades. Our findings of increased BDNF mRNA levels and enhanced
TrkB phosphorylation in HH tissue are consistent with other epi-
lepsy models. It has been previously shown that BDNF is upregu-
lated in multiple brain regions implicated in epileptogenesis,
including hippocampus, neocortex, and ventromedial hypothala-
mus [37–39]. Similarly, seizures induced by hippocampal kindling
lead to increased expression of TrkB, but not TrkA and TrkC, in
the hippocampus [40]. Conditional neuron-specific deletion of
TrkB prevents chronic seizures in the kindling model [41].
We have determined that multiple signaling pathways down-
stream to BDNF-TrkB binding are highly activated in HH tissue.
(A) (B)
(C) (D)
(E)
Figure 4 Enhanced PLCc1-CaMKII signaling in HH. (A and B) Proteins extracted from HH and control tissue specimens were analyzed by immunoblotting
with anti-phospho-PLCc1 (pPLCc1) and anti-b-actin, respectively (A). Densitometric analysis results of immunoblotting data of anti-pPLCc1 from 14 HH and
eight controls are shown (B). (C and D) Proteins extracted from HH and control tissue specimens were analyzed by immunoblotting with anti-CaMKII and
anti-ERK, respectively (C). Densitometric analysis results of immunoblotting data of anti-CaMKII from 14 HH and eight controls are shown (D). **P < 0.01.
(E) Correlation analysis indicates a positive relationship between CaMKII and pPLCc1 levels.
ª 2014 John Wiley & Sons Ltd CNS Neuroscience & Therapeutics 21 (2015) 164–172 169
S. Semaan et al. BDNF-TrkB Signaling in Hypothalamic Hamartoma
TrkB-mediated cellular changes are likely to occur via redundant
activation of multiple pathways during normal development [42].
The details of the link between TrkB activation and downregula-
tion of KCC2 expression are incompletely understood. It is now
generally believed that BDNF binding to TrkB activates three
major intracellular signaling pathways, including PLCc-CaMKII,
Shc-Ras-MAPK, and Shc-PI3K-Akt cascades [16,17] (Figure S3).
Rivera et al. reported that both PLCc- and Shc-mediated signaling
cascades were required for BDNF-induced KCC2 downregulation
[22]. Surprisingly, they showed that in trkBPLC/PLC mice with dele-
tion of the PLCc-coupled pathway, BDNF rather caused upregula-
tion of KCC2 [22]. The discrepancy of results from these studies
could be related to the status of each or both of PLCc- and
Shc-coupled signaling pathways in the context of the actual
experimental settings. Rivera et al. suggested that downregulation
of KCC2 seemed to take place if the Shc pathway was activated in
conjunction with the PLCc pathway, whereas in the absence of
the PLCc signaling KCC2 upregulation was initiated by the Shc
signaling [22]. In the current study, we demonstrate that com-
pared with the control tissue, the Shc-mediated cascades (both
Ras-MAPK and PI3K-Akt) and the PLCc-CAMKII cascade are
highly activated in HH tissue. Concomitantly, KCC2 expression is
downregulated. Although at this stage we cannot dissect these
pathways in individual neurons or specific cell types within the
tissue, our results mainly favor the opinion that both Shc- and
PLCc-coupled pathways are involved in regulation of KCC2
expression.
We have hypothesized that BDNF-TrkB activation and downre-
gulation of KCC2 expression contributes to epileptogenesis in HH
tissue. However, other consequences of activating TrkB deserve
consideration, since each of the activated intracellular signaling
pathways has been associated with seizures and epilepsy. The
ERK MAPK signaling pathway is a highly conserved kinase cas-
cade that has been linked to epileptogenesis in several animal
models [43–48]. In this study, we show that ERK1 and EKR2 are
hyperactivated in HH tissue compared with the normal control.
(A)
(B)
(C)
(D)
Figure 6 Alteration of HH neuronal firing by pharmacological
manipulation of BDNF-TrkB signaling. (A) Typical action potential (AP)
firing from a large HH neuron showing spontaneous and irregular firing at
low frequency as we previously reported [8]. (B) Bath application of BDNF
(10 ng/mL) enhanced AP firing. (A and B) were recorded from the same
neuron. (C, D) Blockade of TrkB signaling by K252a (10 lM) reduced
neuronal firing rate in a large (C), but not in a small (D) HH neuron. (A–D
are representative traces from 10 HH neuron recordings (from 10 HH
patients).
(A)
(B)
(C)
Figure 5 Downregulation of KCC2 in HH. (A and B) Proteins extracted
from HH and control tissue specimens were analyzed by immunoblotting
with anti-KCC2 and anti-b-actin, respectively (A). Densitometric analysis
results of immunoblotting data of anti-KCC2 from 14 HH and eight
controls are shown (B). **P < 0.01. (C) Immunostaining with an anti-KCC2
antibody in tissue sections (arrows) indicates downregulated KCC2
expression in HH versus control tissue. Bar, 50 lm.
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Concomitantly, both BDNF expression and TrkB phosphorylation
are enhanced in the HH tissue. Our results are in agreement with
those from several previous studies. Nateri et al. reported that
active ERKs are predominantly localized to the stratum lucidum
in the hippocampus [48]. Immunhistochemical evidence indi-
cated that although ubiquitously expressed throughout the brain,
during epileptogenesis, TrkB undergoes phosphorylation at the
mossy fiber synapse, and phosphorylated TrkB is specifically
detected in the stratum lucidum [49,50]. The concomitant
activation of TrkB and ERKs and their localization in the same
anatomical region of the brain suggest that activation of the
TrkB-Ras-ERK cascade is probably a key pro-epileptogenic signal-
ing event.
The p38 and JNKs are also well-known MAPKs. Both p38- and
JNK-directed signaling have been involved in pathological condi-
tions including epilepsy, possibly via regulation of neuronal cell
death [51–53]. However, compared with the BDNF-TrkB-Ras-
ERK cascade, little is known about the roles of p38 and JNKs as
downstream effectors of BDNF/TrkB in neuronal signal transduc-
tion [16]. We find increased activation of ERKs, p38 and JNK1 in
HH versus control hypothalamus, suggesting that MAPK-regu-
lated intracellular signals may participate in HH pathogenesis in
some as-yet unknownmanner.
The PI3K-Akt signaling pathway plays a vital role in determin-
ing cell fate and contributes to the onset and progression of many
neurological disorders, including seizures and epilepsy [54,55].
Akt is a serine/threonine kinase that is constitutively inhibited by
PTEN and has downstream effectors that include mammalian tar-
get of rapamycin (mTOR) [55–57]. Chronic hippocampal infusion
of rapamycin (the mTOR kinase inhibitor) blocks mossy fiber
sprouting in a rodent pilocarpine model of temporal lobe epilepsy
[57]. In this study, we find that HH tissue levels of active Akt
(pAkt) and total PTEN display a negative interrelationship (as
expected). This suggests that a further classification of HH cases
into two subgroups (Low pAkt-High PTEN and High pAkt-Low
PTEN) is possible. The significance of this difference between dif-
ferent patients is unclear, but is noteworthy as other anatomical
or physiological features which differentiate HH tissue have been
elusive.
Although the detailed mechanisms are still unclear, our data at
least offer an explanation of how BDNF-TrkB signaling is linked to
KCC2 downregulation and GABAA receptor-mediated neuronal
excitation within the HH lesion. Based on our recent findings
[6–8,36] and the new data presented in this study, we hypothesize
that within the HH tissue, excessive BDNF activates TrkB, causing
hyperactivation of multiple downstream signaling pathways,
including the PLCc-CaMKII, the Shc-Ras-MAPK (ERKs, p38 and
JNK), and the Shc-PI3K-Akt cascades (Fig. S3). These pathways
may act independently or collaboratively to downregulate KCC2
expression, which is the key component for GABA-mediated exci-
tation associated with gelastic seizures. Furthermore, we demon-
strate that activation of BDNF-TrkB signaling (by BDNF) increase
large HH neuron firing rate, while pharmacological inhibition of
TrkB kinase activity markedly reduces the large, but not small, HH
neuronal firing rate. Considering that large HH neurons have
lower KCC2 expression and higher intracellular Cl concentration
[6], the BDNF-TrkB signaling appears to more specifically modu-
late large HH neuronal function, which supports our hypothesis.
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